JOIN OUR TEAM
In 2020, the U.S. market saw four new brands previously sold as prescription drugs enter the nonprescription market: Pataday allergy eye drops Voltaren Arthritis Pain topical NSAID Advil Dual
As 2020 concludes, we are reflecting on the priority of health and safety, and how drastically different our everyday lives are compared to just eight months ago. We have seen major shifts toward the importance of immunity, with less emphasis on treatment of symptoms and more focus on prevention.
The U.S. OTC allergy relief market has seen a period of rapid growth over the past five years, and 2015 was no exception. GlaxoSmithKline’s Rx-to-OTC
Estimated at over $24 billion at the manufacturers’ level in 2014, the U.S. nonprescription drugs market shows interesting opportunities for its players, posting growth in
Growth of the U.S. nonprescription market is primarily driven by Rx-to-OTC switches as they bring former prescription users to the OTC market. Due to an
With the publication of FDA’s NSURE (Nonprescription Safe Use Regulatory Extension) in February 2012, the pharmaceutical industry has been buzzing with potential for new switches,
Infographic representing the U.S. Rx-to-OTC Switch Progression. Download the file here or copy paste the link: https://bit.ly/1cQBmWw
There have been signs recently indicating that the environment is becoming ripe for more Rx-to-OTC switches. Since we last reported on this topic in August
With over half a century of market insights on the U.S. consumer healthcare market, Kline & Company expects that new paradigm shifts in regulations, retail,
Given that many of the most obvious “switchable” drugs and categories have already taken place, opportunities that remain in moving medicines from prescription to nonprescription
